## Per Borghammer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/665840/publications.pdf

Version: 2024-02-01

76326 76900 6,541 137 40 74 citations h-index g-index papers 140 140 140 7020 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Vagotomy and subsequent risk of <scp>P</scp> arkinson's disease. Annals of Neurology, 2015, 78, 522-529.	5.3	625
2	Brain-first versus body-first Parkinson's disease: a multimodalÂimaging case-control study. Brain, 2020, 143, 3077-3088.	7.6	398
3	Pathological αâ€synuclein in gastrointestinal tissues from prodromal <scp>P</scp> arkinson disease patients. Annals of Neurology, 2016, 79, 940-949.	5 <b>.</b> 3	314
4	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurology, The, 2018, 17, 618-628.	10.2	228
5	Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathologica, 2019, 138, 535-550.	7.7	210
6	Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. Journal of Parkinson's Disease, 2019, 9, S281-S295.	2.8	201
7	Prodromal Parkinson disease subtypes â€" key to understanding heterogeneity. Nature Reviews Neurology, 2021, 17, 349-361.	10.1	171
8	Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain, 2015, 138, 2964-2973.	7.6	164
9	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurology, The, 2017, 16, 789-796.	10.2	155
10	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. Brain, 2017, 140, 2002-2011.	7.6	147
11	Brain Energy Metabolism and Blood Flow Differences in Healthy Aging. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1177-1187.	4.3	145
12	Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Structure and Function, 2010, 214, 303-317.	2.3	140
13	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain, 2015, 138, 653-663.	7.6	135
14	Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain, 2018, 141, 496-504.	7.6	135
15	Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. Movement Disorders, 2017, 32, 94-105.	3.9	127
16	How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Movement Disorders, 2018, 33, 48-57.	3.9	114
17	<i>In vivo</i> imaging of neuromelanin in Parkinson's disease using <sup>18</sup> F-AV-1451 PET. Brain, 2016, 139, 2039-2049.	7.6	113
18	A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Research, 2016, 6, 52.	2.5	112

#	Article	IF	Citations
19	Low Cerebral Oxygen Consumption and Blood Flow in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy. Gastroenterology, 2009, 136, 863-871.	1.3	102
20	Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson's Disease: A Colon Transit and Volume Study. Journal of Parkinson's Disease, 2017, 7, 359-367.	2.8	92
21	Normalization in PET group comparison studies—The importance of a valid reference region. Neurolmage, 2008, 40, 529-540.	4.2	87
22	Sex differences of human cortical blood flow and energy metabolism. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2433-2440.	4.3	83
23	The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. Journal of Parkinson's Disease, 2021, 11, 455-474.	2.8	81
24	A deformationâ€based morphometry study of patients with earlyâ€stage Parkinson's disease. European Journal of Neurology, 2010, 17, 314-320.	3.3	80
25	Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson's disease. Neurolmage, 2009, 45, 249-257.	4.2	78
26	Decreased intestinal acetylcholinesterase in early Parkinson disease. Neurology, 2017, 88, 775-781.	1.1	75
27	Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain, 2021, 144, 1853-1868.	7.6	73
28	Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease, 2021, 161, 105557.	4.4	72
29	The Gut and Parkinson's Disease: Hype or Hope?. Journal of Parkinson's Disease, 2018, 8, S31-S39.	2.8	70
30	Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches. Lancet Neurology, The, 2022, 21, 381-392.	10.2	70
31	Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up. Movement Disorders, 2016, 31, 1918-1922.	3.9	58
32	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson's disease. Brain, 2021, 144, 2732-2744.	7.6	57
33	Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neurolmage, 2009, 46, 981-988.	4.2	56
34	Improvement of brain tissue oxygenation by inhalation of carbogen. Neuroscience, 2008, 156, 932-938.	2.3	51
35	Subcortical elevation of metabolism in Parkinson's disease â€" A critical reappraisal in the context of global mean normalization. Neurolmage, 2009, 47, 1514-1521.	4.2	50
36	Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiology of Aging, 2010, 31, 447-463.	3.1	47

3

#	Article	IF	CITATIONS
37	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. Movement Disorders, 2017, 32, 922-927.	3.9	47
38	Gastrointestinal Transit Time in Parkinson's Disease Using a Magnetic Tracking System. Journal of Parkinson's Disease, 2017, 7, 471-479.	2.8	46
39	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiology of Disease, 2018, 117, 211-216.	4.4	46
40	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding. Molecular Imaging and Biology, 2018, 20, 356-360.	2.6	45
41	Normative values for regionâ€specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3Dâ€Transit electromagnet tracking system: Influence of age, gender, and body mass index. Neurogastroenterology and Motility, 2020, 32, e13734.	3.0	45
42	Long-term Risk of Parkinson Disease Following Influenza and Other Infections. JAMA Neurology, 2021, 78, 1461.	9.0	45
43	In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using <sup>11</sup> C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses. Journal of Nuclear Medicine, 2014, 55, 1818-1824.	5.0	40
44	Noradrenergic Deficits in Parkinson Disease Imaged with <sup>11</sup> C-MeNER. Journal of Nuclear Medicine, 2018, 59, 659-664.	5.0	40
45	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ <scp><sup>11</sup>C</scp> ] <scp>UCBâ€J PET</scp> Imaging Study. Movement Disorders, 2021, 36, 2057-2065.	3.9	39
46	Odor identification deficits identify Parkinson's disease patients with poor cognitive performance. Movement Disorders, 2011, 26, 2045-2050.	3.9	38
47	Gastrointestinal Dysfunction in Parkinson's Disease. Journal of Clinical Medicine, 2021, 10, 493.	2.4	37
48	Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurologica Scandinavica, 2012, 125, 303-310.	2.1	36
49	Gastric emptying in Parkinson's disease – A mini-review. Parkinsonism and Related Disorders, 2018, 55, 18-25.	2.2	36
50	Constipation and risk of Parkinson's disease: A Danish population-based cohort study. Parkinsonism and Related Disorders, 2016, 28, 18-22.	2.2	35
51	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiology of Disease, 2018, 115, 9-16.	4.4	35
52	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
53	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. Journal of Parkinson's Disease, 2021, 11, 1677-1687.	2.8	34
54	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. Movement Disorders, 2018, 33, 1006-1010.	3.9	33

#	Article	IF	CITATIONS
55	18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma. Clinical Nuclear Medicine, 2019, 44, 605-611.	1.3	30
56	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. Journal of Parkinson's Disease, 2021, 11, 1209-1219.	2.8	29
57	Salivary Acetylcholinesterase Activity Is Increased in Parkinson's Disease: A Potential Marker of Parasympathetic Dysfunction. Parkinson's Disease, 2015, 2015, 1-7.	1.1	28
58	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer's Disease. International Journal of Alzheimer's Disease, 2018, 2018, 1-5.	2.0	28
59	Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study. Parkinsonism and Related Disorders, 2020, 75, 63-69.	2.2	27
60	Cerebral oxygen metabolism in patients with early Parkinson's disease. Journal of the Neurological Sciences, 2012, 313, 123-128.	0.6	26
61	Olfactory function in Parkinson's Disease - effects of training. Acta Neurologica Scandinavica, 2015, 132, 395-400.	2.1	24
62	Perfusion and metabolism imaging studies in Parkinson's disease. Danish Medical Journal, 2012, 59, 84466.	0.5	24
63	Imaging Systemic Dysfunction in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2016, 16, 51.	4.2	23
64	18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas. Clinical Nuclear Medicine, 2019, 44, 550-559.	1.3	23
65	Clinical heterogeneity in Parkinson's disease revisited: a latent profile analysis. Acta Neurologica Scandinavica, 2012, 125, 311-318.	2.1	20
66	Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid $\hat{Al^2}$ . Parkinsonism and Related Disorders, 2021, 83, 71-78.	2.2	20
67	Spatial distribution of malignant tissue in gliomas: correlations of $<$ sup $>11sup>C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging. Acta Radiologica, 2015, 56, 1135-1144.$	1.1	19
68	Imaging Parkinson's disease below the neck. Npj Parkinson's Disease, 2017, 3, 15.	5.3	19
69	PET Visualized Stimulation of the Vestibular Organ in Menière's Disease. Frontiers in Neurology, 2020, 11, 11.	2.4	19
70	Effect of memantine on CBF and CMRO <sub>2</sub> in patients with early Parkinson's disease. Acta Neurologica Scandinavica, 2008, 117, 317-323.	2.1	18
71	Objective intestinal function in patients with idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2019, 58, 28-34.	2.2	18
72	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. Journal of Neurology, 2020, 267, 2296-2300.	3.6	18

#	Article	IF	CITATIONS
73	Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI. Nuclear Medicine Communications, 2015, 36, 1084-1090.	1.1	17
74	Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson's disease. Sleep, 2021, 44, .	1.1	17
75	Is constipation in Parkinson's disease caused by gut or brain pathology?. Parkinsonism and Related Disorders, 2018, 55, 6-7.	2.2	15
76	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. Neurobiology of Disease, 2021, 152, 105295.	4.4	15
77	Molecular Imaging and the Neuropathologies of Parkinson's Disease. Current Topics in Behavioral Neurosciences, 2011, 11, 117-148.	1.7	14
78	Cholinergic PET imaging in infections and inflammation using 11C-donepezil and 18F-FEOBV. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 449-458.	6.4	14
79	Imaging the Autonomic Nervous System in Parkinson's Disease. Current Neurology and Neuroscience Reports, 2018, 18, 79.	4.2	14
80	Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms. Neurogastroenterology and Motility, 2020, 32, e13948.	3.0	14
81	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2020, 81, 89-93.	2.2	14
82	Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 1392.	2.4	14
83	The Parkinsonian Personality and Concomitant Depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 48-55.	1.8	14
84	Does vagotomy reduce the risk of Parkinson's disease: The authors reply. Annals of Neurology, 2015, 78, 1012-1013.	<b>5.</b> 3	13
85	Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 251-274.	2.0	13
86	Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomolecules, 2022, 12, 168.	4.0	13
87	Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression. Brain, 2022, 145, 3162-3178.	7.6	13
88	Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders. International Journal of Clinical Practice, 2014, 68, 1345-1351.	1.7	12
89	Multimodal 18 F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. World Neurosurgery, 2017, 108, 989.e1-989.e8.	1.3	12
90	Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Diseaseâ€"An Ultrasound Case-Control Study. Frontiers in Neurology, 2021, 12, 681413.	2.4	12

#	Article	IF	CITATIONS
91	Kinetic Modelling of Infection Tracers [ <sup>18</sup> F]FDG, [ <sup>68</sup> Ga]Ga-Citrate, [ <sup>11</sup> C]Methionine, and [ <sup>11</sup> C]Donepezil in a Porcine Osteomyelitis Model. Contrast Media and Molecular Imaging, 2017, 2017, 1-18.	0.8	11
92	Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm. Clinical Neurophysiology, 2018, 129, 541-547.	1.5	11
93	Evaluation of Active Brown Adipose Tissue by the Use of Hyperpolarized [1-13C]Pyruvate MRI in Mice. International Journal of Molecular Sciences, 2018, 19, 2597.	4.1	11
94	Utility of C-methionine and C-donepezil for imaging of induced osteomyelitis in a juvenile porcine model: comparison to autologous In-labelled leukocytes, Tc-DPD, and F-FDG. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 286-300.	1.0	11
95	Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study. Journal of Parkinson's Disease, 2020, 10, 161-171.	2.8	10
96	Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies. Frontiers in Aging Neuroscience, 2022, 14, .	3.4	10
97	Pseudoprogression after proton radiotherapy for pediatric low grade glioma. Acta Oncol $ ilde{A}^3$ gica, 2015, 54, 1701-1702.	1.8	9
98	Preventing Parkinson disease by vagotomy. Neurology, 2017, 88, 1982-1983.	1.1	9
99	Positron emission tomography visualized stimulation of the vestibular organ is localized in Heschl's gyrus. Human Brain Mapping, 2020, 41, 185-193.	3.6	9
100	Skin Temperature in Parkinson's Disease Measured by Infrared Thermography. Parkinson's Disease, 2020, 2020, 1-7.	1.1	9
101	Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET. Nuclear Medicine and Biology, 2022, 112-113, 52-58.	0.6	9
102	Preclinical evaluation of potential infectionâ€imaging probe [ <sup>68</sup> Ga] <scp>Gaâ€DOTAâ€Kâ€A9</scp> in sterile and infectious inflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 780-795.	1.0	8
103	Enteric cholinergic neuropathy in patients with diabetes: Nonâ€invasive assessment with positron emission tomography. Neurogastroenterology and Motility, 2020, 32, e13731.	3.0	8
104	Cardiac <sup>11</sup> C-Donepezil Binding Increases With Age in Healthy Humans: Potentially Signifying Sigma-1 Receptor Upregulation. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 365-370.	2.0	7
105	In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients. Neurogastroenterology and Motility, 2020, 32, e13759.	3.0	7
106	Normative values for gastric motility assessed with the 3Dâ€transit electromagnetic tracking system. Neurogastroenterology and Motility, 2020, 32, e13829.	3.0	7
107	Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy. Journal of Neurogastroenterology and Motility, 2021, 27, 390-399.	2.4	7
108	Non-invasive quantification of tumor blood flow in prostate cancer using O-HO PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 292-302.	1.0	7

#	Article	IF	Citations
109	False-Positive 123I-FP-CIT Scintigraphy and Suggested Dopamine Transporter Upregulation Due to Chronic Modafinil Treatment. Clinical Nuclear Medicine, 2014, 39, e87-e88.	1.3	6
110	Vagotomy and subsequent development of diabetes – A nested case–control study. Metabolism: Clinical and Experimental, 2016, 65, 954-960.	3.4	6
111	Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation. Journal of Parkinson's Disease, 2017, 7, 645-652.	2.8	6
112	Tonsillectomy and risk of Parkinson's disease: A danish nationwide populationâ€based cohort study. Movement Disorders, 2018, 33, 321-324.	3.9	6
113	The Logic and Pitfalls of Parkinson's as Brain―Versus Bodyâ€First Subtypes. Movement Disorders, 2021, 36, 785-786.	3.9	6
114	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. Brain, 2021, 144, 1498-1508.	7.6	6
115	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study. EJNMMI Research, 2022, 12, 17.	2.5	6
116	Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease. Archives of Neurology, 2005, 62, 1480.	4.5	5
117	Variable ATP Yields and Uncoupling of Oxygen Consumption in Human Brain. Advances in Experimental Medicine and Biology, 2011, 701, 243-248.	1.6	5
118	The parkinsonian personality and concomitant depression. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 48-55.	1.8	5
119	Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up. Parkinsonism and Related Disorders, 2022, 101, 99-104.	2.2	5
120	Functional image-guided dose escalation in gliomas using of state-of-the-art photon vs. proton therapy. Acta $Oncol\tilde{A}^3$ gica, 2017, 56, 826-831.	1.8	4
121	The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 185-192.	1.0	4
122	Colonic volume and gastrointestinal symptoms in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e46.	2.2	3
123	Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls. Journal of Clinical and Experimental Neuropsychology, 2020, 42, 425-435.	1.3	3
124	Fasting gallbladder volume is increased in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 87, 56-60.	2.2	3
125	Reply. Annals of Neurology, 2015, 78, 835-835.	5.3	2
126	Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 906-910.	6.4	2

#	Article	IF	CITATIONS
127	A Screening-Based Method for Identifying Patients with REM Sleep Behaviour Disorder in a Danish Community Setting. Journal of Parkinson's Disease, 2020, 10, 1249-1253.	2.8	2
128	Gastrointestinal transit time and heart rate variability in patients with mild acquired brain injury. PeerJ, 2018, 6, e4912.	2.0	2
129	Absent 18F-FDG Uptake in the Brain—Unsuspected Brain Death. Clinical Nuclear Medicine, 2020, 45, e433-e434.	1.3	1
130	Radionuclide Imaging of the Gut–Brain Axis in Parkinson Disease. Journal of Nuclear Medicine, 2021, 62, 1504-1505.	5.0	1
131	Cortical Activity During an Attack of Ménière's Disease—A Case Report. Frontiers in Neurology, 2021, 12, 669390.	2.4	1
132	Partial volume correction using cortical surfaces. , 2010, , .		0
133	Reply to the letter to the Editor: Comment to Barichella and colleagues. Movement Disorders, 2017, 32, 631-631.	3.9	O
134	Assessing autonomic dysfunction with functional imaging in Parkinson's disease. International Review of Movement Disorders, 2021, , 91-118.	0.1	0
135	Asymmetric Distribution of Dopamine Transporters in Premorbid Corticobasal Syndrome—A Case Report. Movement Disorders Clinical Practice, 2021, 8, 607-609.	1.5	О
136	Acetylcholinesterase-associated inflammation in patients with giant cell arteritis. Evaluation by histology and 11C-donepezil PET/CT. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 20-25.	0.8	0
137	Intestinal Transit in Early Moderate Parkinson's Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate. Parkinson's Disease, 2022, 2022, 1-8.	1.1	O